Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Key Inclusion Criteria: * Written informed consent must have been obtained before any assessment was performed. Where relevant, a legal representative will also have signed the informed study consent according to local laws and regulations. * Subjects must have been able to understand and communicate with the investigator and comply with the requirements of the study. * Men or women at least 18 years of age at time of screening. * Body weight of ≥ 90 kg at the time of randomization. * Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization. * Moderate to severe psoriasis as defined at randomization by: * Psoriasis Area and Severity Index (PASI) score of 12 or greater, and * Investigator's Global Assessment (IGA) mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and * Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater. * Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by: * topical treatment and/or, * phototherapy and/or, * previous systemic therapy. Key Exclusion Criteria: * Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at screening or Randomization. * Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to. Subjects not willing to limit ultraviolet (UV) light exposure (e.g., sun…